In tumor cells, mechanisms that inhibit GSK-3β-induced phosphorylation of β-catenin block its interaction with the E3 ubiquitin ligase receptor, β-TrCP, which prevents β-catenin ubiquitination and degradation, and ultimately leads to β-catenin activation [24], [25]. The gene discussed is GSK3B; the disease is neoplasm.